Literature DB >> 31421272

The effects of topical antibiotics on eradication and acquisition of third-generation cephalosporin and carbapenem-resistant Gram-negative bacteria in ICU patients; a post hoc analysis from a multicentre cluster-randomized trial.

N L Plantinga1, B H J Wittekamp2, C Brun-Buisson3, M J M Bonten1.   

Abstract

OBJECTIVES: The aim was to quantify the effects of selective digestive tract decontamination (SDD) consisting of a mouth paste and gastro-enteral suspension, selective oropharyngeal decontamination with a mouth paste (SOD) and 1-2% chlorhexidine (CHX) mouthwash on eradication and acquisition of carriage of third-generation cephalosporin-resistant Enterobacterales (3GCR-E) and carbapenem-resistant Gram-negative bacteria (CR-GNB) in Intensive Care Unit (ICU) patients.
METHODS: This was a nested cohort study within a cluster-randomized cross-over trial in six European countries and 13 ICUs with 8665 patients. Eradication and acquisition during ICU stay of 3GCR-E and CR-GNB were investigated separately in the rectum and respiratory tract for the three interventions and compared with standard care (SC) using Cox-regression competing events analyses.
RESULTS: Adjusted cause specific hazard ratios (CSHR) for eradication of rectal carriage for SDD were 1.76 (95% CI 1.31-2.36) for 3GCR-E and 3.17 (95% CI 1.60-6.29) for CR-GNB compared with SC. For the respiratory tract, adjusted CSHR for eradication of 3GCR-E were 1.47 (0.98-2.20) for SDD and 1.38 (0.92-2.06) for SOD compared with SC, and for eradication of CR-GNB these were 0.77 (0.41- 1.45) for SDD and 0.81 (0.44-1.51) for SOD, compared with SC. Adjusted CSHRs for acquisition of rectal carriage during SDD (compared with SC) were 0.51 (0.40-0.64) for 3GCR-E and of 0.56 (0.40-0.78) for CR-GNB. Adjusted CSHRs for acquiring respiratory tract carriage with 3GCR-E compared with SC were 0.38 (0.28-0.50) for SDD and 0.55 (0.42-0.71) for SOD, and for CR-GNB 0.46 (0.33-0.64) during SDD and 0.60 (0.44-0.81) during SOD, respectively. SOD was not associated with eradication or acquisition of 3GCR-E and CR-GNB in the rectum.
CONCLUSIONS: Among mechanically ventilated ICU patients, SDD was associated with more eradication and less acquisition of 3GCR-E and CR-GNB in the rectum than SC. SDD and SOD were associated with less acquisition of both 3GCR-E and CR-GNB than SC in the respiratory tract.
Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Colonization; Decontamination; ESBL; Gram-negative bacteria; ICU; SDD

Mesh:

Substances:

Year:  2019        PMID: 31421272     DOI: 10.1016/j.cmi.2019.08.001

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  4 in total

1.  Less daily oral hygiene is more in the ICU: no.

Authors:  Bastiaan H Wittekamp; Nienke L Plantinga
Journal:  Intensive Care Med       Date:  2021-02-08       Impact factor: 17.440

2.  Identification of carbapenems resistant genes on biofilm forming K. pneumoniae from urinary tract infection.

Authors:  Govindan Nadar Rajivgandhi; Naiyf S Alharbi; Shine Kadaikunnan; Jamal M Khaled; Chelliah Chenthis Kanisha; Govindan Ramachandran; Natesan Manoharan; Khalid F Alanzi
Journal:  Saudi J Biol Sci       Date:  2020-12-29       Impact factor: 4.219

Review 3.  Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome.

Authors:  Laia Fernández-Barat; Ruben López-Aladid; Antoni Torres
Journal:  EBioMedicine       Date:  2020-09-16       Impact factor: 8.143

4.  Incidence and risk factors for acquired colonization and infection due to extended-spectrum beta-lactamase-producing Gram-negative bacilli: a retrospective analysis in three ICUs with low multidrug resistance rate.

Authors:  Nicolas Massart; Christophe Camus; François Benezit; Mikael Moriconi; Pierre Fillatre; Yves Le Tulzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-02       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.